November 12, 2008

home / publications / obtn / nov2008
Anti-Lung Cancer Compound ASA404 Progresses to Phase III

Anti-Lung Cancer Compound ASA404 Progresses to Phase III

Peter Ciszewski
November 17th 2008
Article

A pivotal phase III study is currently underway to evaluate the efficacy and safety of Novartis’ novel anti-cancer compound ASA404 in patients with non–small cell lung cancer (NSCLC).

Site Logo

Highlights of 2nd Annual ILCA Conference: Cutting-edge Treatments for Hepatocellular Carcinoma

Onclive Team
November 17th 2008
Article

Cutting-edge treatments for hepatocellular carcinoma, including contrast-enhanced ultrasound, combined CRT/TACE, sorafenib, & LCCRT for patients with PVT.

Site Logo

Beyond Genetics: Emerging Breakthroughs in Breast Cancer Battle

Diane West
November 17th 2008
Article

Key findings from the 2008 ASCO Breast Cancer conference; updates on goserelin, capecitabine, docetaxel & lapatinib.

Site Logo

Highlights from Two Key Symposiums: Reporting on new research and emerging trends in breast and liver cancer.

E. Roy Berger, MD, FACP;Physician Editor
November 17th 2008
Article

Reporting on new research and emerging trends in breast and liver cancer.